Workshop on MedDRA and WHO DD terminology | 52313
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 1478 350008

Workshop on MedDRA and WHO DD terminology

International Conference on Clinical Trials

July 27-29, 2015 Orlando-FL, USA

Samina Qureshi

ScientificTracks Abstracts-Workshop: J Clin Trials

Abstract :

The capture of safety data in the health care/life sciences context involves the use of many diverse terminologies. The purpose
of these many terminologies is varied, ranging from capturing adverse events to categorizing diagnoses and procedures.
The most important use of these terminologies involves the performance of good quality coding. Employing high quality and
superior standards of coding translates into choosing terms within the respective terminology that most closely and accurately
captures the concept observed or captured. Whether that concept is a product name in the case of pharmaceuticals or expression
of an adverse event, the principle objective remains the same: Maintaining the integrity of information. The primary purpose
of developing coding terminologies is to provide a uniform, consistent and reliable methodology to express concepts without
losing expression of the integrity of the event. The correct use of coding terminology allows for the capture of “good” data and
the production of aggregate results that lend themselves to reliable and meaningful analysis. Such a process ensures accurate
signal detection that is neither diluted nor magnified. Because there are numerous terminologies, this workshop focuses on
those described in the Medical Dictionary for Regulatory Activities (“MedDRA”) which is often used to capture adverse events
after drug exposure and the World Health Organization’s Drug Dictionary (“WHO-DD”) which is used to capture concomitant
medications often used in pre and post marketing. The structure and content of each terminology will be discussed as well as
demonstration of good coding practices. Common coding challenges will also be discussed and best practices employed in the

Biography :

Samina Qureshi is the Medical Director of the Health Sciences Division at PSI International Inc. She is a physician and is also pursuing an Advanced degree
in Regulatory Science at the prestigious Johns Hopkins University. She is also an expert in various dictionaries, including the Medical Dictionary for Regulatory
Activities (MedDRA), the World Health Organization Drug Dictionary (WHO-DD) and International Classification of Disease (ICD 9/10). She has supported Clinical
and Pharmacovigilance activities at a senior level with over 20 pharmaceutical clients, the World Health Organization- Uppsala Monitoring Center as well as the US
Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Adverse Events Reporting Programs Support; National Institutes of Health
(NIH) and at U.S. Army Medical Materiel Development Activity (USAMMDA). providing training to data management staff.